Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）
10.3969/j.issn.1001-5256.2023.10.010
- VernacularTitle:《2023年国际多学科专家共识： 代谢相关脂肪性肝病和心血管疾病风险》摘译
- Author:
Xiaodong ZHOU
1
;
Na TIAN
2
;
Minghua ZHENG
2
Author Information
1. Department of Cardiovascular Medicine， The Heart Center，The First Affiliated Hospital of Wenzhou Medical University， Wenzhou， Zhejiang 325000， China
2. Department of Infectious Diseases， The First Affiliated Hospital of Wenzhou Medical University， Wenzhou， Zhejiang 325000， China
- Publication Type:Journal Article
- Keywords:
Metabolic （dysfunction）－Associated Fatty Liver Disease;
Non－Alcoholic Fatty Liver Disease;
Cardiovascular Diseases;
Consensus
- From:
Journal of Clinical Hepatology
2023;39(10):2336-2339
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease （MAFLD） is a common chronic liver disease around the world， affecting more than a quarter of the adult population worldwide. MAFLD is characterized by the co-occurrence of hepatic steatosis and metabolic disturbance. As a metabolic disorder， MAFLD shares a similar pathogenesis with cardiovascular disease （CVD）， and both diseases are closely associated with the well-established cardiovascular risk factors such as obesity， type 2 diabetes， and atherogenic dyslipidemia. An increasing amount of evidence has shown that MAFLD is closely associated with CVD； however， as a new risk factor for CVD， MAFLD differs from traditional risk factors for CVD， which requires further investigation. In this context， this consensus statement used the Delphi method to achieve a consensus on the association between MAFLD and the risk of CVD through two rounds of surveys and discussed the association between MAFLD and CVD in terms of epidemiological and clinical characteristics， as well as a range of topics including pathophysiological mechanisms， surveillance， and management.
